Vbi Vaccines Inc (VBIV)

$0.5695

Market is closed - opens 7 PM, 02 May 2024

Insights on Vbi Vaccines Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 6.62M → 853.0K (in $), with an average decrease of 43.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -44.62M → -13.0K (in $), with an average increase of 52426.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 54.6% return, outperforming this stock by 134.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 249.5% return, outperforming this stock by 348.9%

Performance

  • $0.56
    $0.58
    $0.57
    downward going graph

    2.28%

    Downside

    Day's Volatility :3.95%

    Upside

    1.71%

    downward going graph
  • $0.45
    $3.47
    $0.57
    downward going graph

    21.05%

    Downside

    52 Weeks Volatility :87.03%

    Upside

    83.57%

    downward going graph

Returns

PeriodVbi Vaccines IncSector (Health Care)Index (Russel 2000)
3 Months
-17.34%
-1.0%
0.0%
6 Months
-4.69%
10.9%
0.0%
1 Year
-80.29%
5.2%
2.1%
3 Years
-99.41%
15.9%
-21.9%

Highlights

Market Capitalization
16.8M
Book Value
$0.32
Earnings Per Share (EPS)
-6.03
PEG Ratio
0.0
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
-1449.47%
Return On Assets TTM
-28.57%
Return On Equity TTM
-258.99%
Revenue TTM
8.7M
Revenue Per Share TTM
0.56
Quarterly Revenue Growth YOY
191.1%
Gross Profit TTM
-10.2M
EBITDA
-53.3M
Diluted Eps TTM
-6.03
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.39
EPS Estimate Next Year
-0.51
EPS Estimate Current Quarter
-0.53
EPS Estimate Next Quarter
-0.47

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Vbi Vaccines Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 777.96%

Current $0.57
Target $5.00

Company Financials

FY18Y/Y Change
Revenue
3.4M
↑ 287.86%
Net Income
-63.6M
↑ 63.1%
Net Profit Margin
-1.9K%
↑ 2612.41%
FY19Y/Y Change
Revenue
2.2M
↓ 33.8%
Net Income
-55.8M
↓ 12.26%
Net Profit Margin
-2.5K%
↓ 616.93%
FY20Y/Y Change
Revenue
1.1M
↓ 52.23%
Net Income
-47.3M
↓ 15.27%
Net Profit Margin
-4.5K%
↓ 1944.13%
FY21Y/Y Change
Revenue
631.0K
↓ 40.53%
Net Income
-72.7M
↑ 53.64%
Net Profit Margin
-11.5K%
↓ 7056.73%
FY22Y/Y Change
Revenue
1.1M
↑ 71.47%
Net Income
-141.0M
↑ 94.01%
Net Profit Margin
-13.0K%
↓ 1513.42%
FY23Y/Y Change
Revenue
8.7M
↑ 702.4%
Net Income
-92.8M
↓ 34.14%
Net Profit Margin
-1.1K%
↑ 11957.6%
Q4 FY22Q/Q Change
Revenue
293.0K
↓ 7.57%
Net Income
-19.6M
↓ 30.06%
Net Profit Margin
-6.7K%
↑ 2154.78%
Q1 FY23Q/Q Change
Revenue
485.0K
↑ 65.53%
Net Income
-37.4M
↑ 90.59%
Net Profit Margin
-7.7K%
↓ 1014.51%
Q2 FY23Q/Q Change
Revenue
720.0K
↑ 48.45%
Net Income
-44.6M
↑ 19.26%
Net Profit Margin
-6.2K%
↑ 1517.55%
Q3 FY23Q/Q Change
Revenue
6.6M
↑ 820.0%
Net Income
-20.4M
↓ 54.19%
Net Profit Margin
-308.64%
↑ 5889.69%
Q4 FY23Q/Q Change
Revenue
853.0K
↓ 87.12%
Net Income
-13.0K
↓ 99.94%
Net Profit Margin
-1.52%
↑ 307.12%
Q1 FY24Q/Q Change
Revenue
853.0K
↑ 0.0%
Net Income
-13.0K
↑ 0.0%
Net Profit Margin
-1.52%
↑ 0.0%
FY18Y/Y Change
Total Assets
137.6M
↓ 5.53%
Total Liabilities
39.5M
↑ 52.58%
FY19Y/Y Change
Total Assets
122.2M
↓ 11.19%
Total Liabilities
33.9M
↓ 14.0%
FY20Y/Y Change
Total Assets
209.4M
↑ 71.33%
Total Liabilities
37.7M
↑ 10.96%
FY21Y/Y Change
Total Assets
210.3M
↑ 0.43%
Total Liabilities
66.4M
↑ 76.27%
FY22Y/Y Change
Total Assets
155.1M
↓ 26.25%
Total Liabilities
90.9M
↑ 36.94%
FY23Y/Y Change
Total Assets
87.0M
↓ 43.93%
Total Liabilities
79.4M
↓ 12.65%
Q4 FY22Q/Q Change
Total Assets
155.1M
↓ 9.84%
Total Liabilities
90.9M
↑ 3.1%
Q1 FY23Q/Q Change
Total Assets
128.5M
↓ 17.17%
Total Liabilities
83.4M
↓ 8.23%
Q2 FY23Q/Q Change
Total Assets
88.3M
↓ 31.25%
Total Liabilities
79.6M
↓ 4.62%
Q3 FY23Q/Q Change
Total Assets
100.8M
↑ 14.11%
Total Liabilities
80.9M
↑ 1.65%
Q4 FY23Q/Q Change
Total Assets
87.0M
↓ 13.73%
Total Liabilities
79.4M
↓ 1.82%
Q1 FY24Q/Q Change
Total Assets
87.0M
↑ 0.0%
Total Liabilities
79.4M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-45.5M
↑ 45.1%
Investing Cash Flow
-6.0M
↑ 935.06%
Financing Cash Flow
43.6M
↓ 35.13%
FY19Y/Y Change
Operating Cash Flow
-48.7M
↑ 6.98%
Investing Cash Flow
-3.7M
↓ 38.71%
Financing Cash Flow
37.4M
↓ 14.22%
FY20Y/Y Change
Operating Cash Flow
-47.1M
↓ 3.41%
Investing Cash Flow
-26.0M
↑ 607.87%
Financing Cash Flow
122.4M
↑ 227.12%
FY21Y/Y Change
Operating Cash Flow
-39.9M
↓ 15.18%
Investing Cash Flow
23.2M
↓ 189.06%
Financing Cash Flow
44.3M
↓ 63.81%
FY22Y/Y Change
Operating Cash Flow
-73.7M
↑ 84.66%
Investing Cash Flow
-4.3M
↓ 118.76%
Financing Cash Flow
19.4M
↓ 56.09%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.0M
↑ 10.26%
Investing Cash Flow
-1.5M
↑ 11.69%
Financing Cash Flow
12.0K
↓ 99.94%

Technicals Summary

Sell

Neutral

Buy

Vbi Vaccines Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Vbi Vaccines Inc
Vbi Vaccines Inc
-18.64%
-4.69%
-80.29%
-99.41%
-99.0%
Moderna, Inc.
Moderna, Inc.
7.58%
56.48%
-15.18%
-40.08%
293.3%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.36%
10.34%
13.15%
84.9%
169.37%
Novo Nordisk A/s
Novo Nordisk A/s
2.17%
28.02%
54.56%
243.01%
428.79%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.78%
6.8%
16.22%
84.51%
137.19%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Vbi Vaccines Inc
Vbi Vaccines Inc
NA
NA
0.0
-1.39
-2.59
-0.29
NA
0.32
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Vbi Vaccines Inc
Vbi Vaccines Inc
Buy
$16.8M
-99.0%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
293.3%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
169.37%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
428.79%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
137.19%
28.81
36.68%

Institutional Holdings

  • Perceptive Advisors LLC

    5.83%

  • Alyeska Investment Group, L.P.

    2.94%

  • Vanguard Group Inc

    0.78%

  • Geode Capital Management, LLC

    0.59%

  • BlackRock Inc

    0.47%

  • CAMBRIDGE Invest RESEARCH ADVISORS, INC.

    0.37%

Corporate Announcements

  • Vbi Vaccines Inc Earnings

    Vbi Vaccines Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.

Organization
Vbi Vaccines Inc
Employees
131
CEO
Mr. Jeffery R. Baxter FCMA
Industry
Health Technology

Discover More

FAQs